

Shahinaz Gadalla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3954433/publications.pdf>

Version: 2024-02-01

135
papers

3,682
citations

147801

31
h-index

161849

54
g-index

140
all docs

140
docs citations

140
times ranked

6085
citing authors

#	ARTICLE	IF	CITATIONS
1	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
2	Risks of myeloid malignancies in patients with autoimmune conditions. <i>British Journal of Cancer</i> , 2009, 100, 822-828.	6.4	222
3	Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. <i>International Journal of Cancer</i> , 2009, 125, 398-405.	5.1	221
4	Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. <i>Aging</i> , 2010, 2, 867-874.	3.1	120
5	Consensus-based care recommendations for adults with myotonic dystrophy type 1. <i>Neurology: Clinical Practice</i> , 2018, 8, 507-520.	1.6	115
6	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1238-1243.	2.0	108
7	Hematopoietic Malignancies Associated with Viral and Alcoholic Hepatitis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3069-3075.	2.5	100
8	Cancer Risk Among Patients With Myotonic Muscular Dystrophy. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2480-6.	7.4	99
9	Telomeres and the natural lifespan limit in humans. <i>Aging</i> , 2017, 9, 1130-1142.	3.1	82
10	Association Between Donor Leukocyte Telomere Length and Survival After Unrelated Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 594.	7.4	73
11	Exploring Patient-Physician Communication in Breast Cancer Care for African American Women Following Primary Treatment. <i>Oncology Nursing Forum</i> , 2008, 35, 836-843.	1.2	68
12	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
13	Family Perspectives on Communication With Healthcare Providers During End-of-Life Cancer Care. <i>Oncology Nursing Forum</i> , 2006, 33, 753-760.	1.2	59
14	A population-based assessment of mortality and morbidity patterns among patients with thymoma. <i>International Journal of Cancer</i> , 2011, 128, 2688-2694.	5.1	59
15	Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. <i>British Journal of Haematology</i> , 2020, 189, 1171-1181.	2.5	58
16	LINE-1 methylation is inherited in familial testicular cancer kindreds. <i>BMC Medical Genetics</i> , 2010, 11, 77.	2.1	55
17	Effect of pre-analytic variables on the reproducibility of qPCR relative telomere length measurement. <i>PLoS ONE</i> , 2017, 12, e0184098.	2.5	55
18	HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. <i>Blood</i> , 2022, 139, 1452-1468.	1.4	52

#	ARTICLE	IF	CITATIONS
19	Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2007, 46, 620-627.	3.7	50
20	Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1342-1349.	2.0	50
21	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 367-378.	2.0	50
22	Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based caseâ€“control study. <i>British Journal of Cancer</i> , 2009, 100, 817-821.	6.4	48
23	Method comparison studies of telomere length measurement using qPCR approaches: A critical appraisal of the literature. <i>PLoS ONE</i> , 2021, 16, e0245582.	2.5	43
24	Correlation of Leukocyte Telomere Length Measurement Methods in Patients with Dyskeratosis Congenita and in Their Unaffected Relatives. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1765.	4.1	42
25	Pesticide Use and Relative Leukocyte Telomere Length in the Agricultural Health Study. <i>PLoS ONE</i> , 2015, 10, e0133382.	2.5	42
26	Telomere biology in hematopoiesis and stem cell transplantation. <i>Blood Reviews</i> , 2011, 25, 261-269.	5.7	39
27	Correlates of tumor development in patients with myotonic dystrophy. <i>Journal of Neurology</i> , 2012, 259, 2161-2166.	3.6	38
28	Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study. <i>PLoS Medicine</i> , 2021, 18, e1003615.	8.4	38
29	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	5.2	37
30	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	5.2	35
31	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
32	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
33	Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors. <i>Journal of Neurology</i> , 2016, 263, 492-498.	3.6	32
34	Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. <i>Blood Advances</i> , 2018, 2, 1243-1249.	5.2	30
35	The relationship between DNA methylation and telomere length in dyskeratosis congenita. <i>Aging Cell</i> , 2012, 11, 24-28.	6.7	28
36	Telomere length and risk of glioma. <i>Cancer Epidemiology</i> , 2013, 37, 935-938.	1.9	28

#	ARTICLE	IF	CITATIONS
37	Measurement of Telomere Length for Longitudinal Analysis: Implications of Assay Precision. American Journal of Epidemiology, 2021, 190, 1406-1413.	3.4	28
38	The Long and Short of Telomeres and Cancer Association Studies. Journal of the National Cancer Institute, 2013, 105, 448-449.	6.3	25
39	Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 862-868.	2.5	25
40	Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the <scp>U</scp>. <scp>K</scp>. <scp>C</scp>linical <scp>P</scp>ractice <scp>R</scp>esearch <scp>D</scp>atalink. International Journal of Cancer, 2018, 142, 1174-1181.	5.1	25
41	Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia. American Journal of Human Genetics, 2020, 106, 264-271.	6.2	25
42	Prevalence of smoking among rural secondary school students in Qalyobia governorate. Journal of the Egyptian Society of Parasitology, 2003, 33, 1031-50.	0.2	25
43	Cancer Risk in Myotonic Dystrophy Type I: Evidence of a Role for Disease Severity. JNCI Cancer Spectrum, 2018, 2, pky052.	2.9	24
44	The Effect of Cancer Treatments on Telomere Length: A Systematic Review of the Literature. Journal of the National Cancer Institute, 2018, 110, 1048-1058.	6.3	24
45	Water pipe (Sisha) smoking in cafes in Egypt. Journal of the Egyptian Society of Parasitology, 2003, 33, 1073-85.	0.2	24
46	Telomeres in Molecular Epidemiology Studies. Progress in Molecular Biology and Translational Science, 2014, 125, 113-131.	1.7	23
47	Telomere Length Calibration from qPCR Measurement: Limitations of Current Method. Cells, 2018, 7, 183.	4.1	23
48	Association Between Aspirin Use and Biliary Tract Cancer Survival. JAMA Oncology, 2019, 5, 1802.	7.1	23
49	Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. Gut, 2019, 68, 1458-1464.	12.1	23
50	Quantifying Cancer Absolute Risk and Cancer Mortality in the Presence of Competing Events after a Myotonic Dystrophy Diagnosis. PLoS ONE, 2013, 8, e79851.	2.5	23
51	Effect of Recipient Age and Stem Cell Source on the Association between Donor Telomere Length and Survival after Allogeneic Unrelated Hematopoietic Cell Transplantation for Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2016, 22, 2276-2282.	2.0	22
52	Cancer phenotype in myotonic dystrophy patients: Results from a meta-analysis. Muscle and Nerve, 2018, 58, 517-522.	2.2	22
53	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biology of Blood and Marrow Transplantation, 2019, 25, 270-278.	2.0	21
54	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21

#	ARTICLE	IF	CITATIONS
55	The limitations of qPCR telomere length measurement in diagnosing dyskeratosis congenita. <i>Molecular Genetics & Genomic Medicine</i> , 2016, 4, 475-479.	1.2	20
56	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2397-2409.	1.6	19
57	Patient Understanding of Diabetes Self-Management: Participatory Decision-Making in Diabetes Care. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 723-730.	2.2	18
58	Autoimmune diseases and breast cancer risk by tumor hormone receptor status among elderly women. <i>International Journal of Cancer</i> , 2018, 142, 1202-1208.	5.1	18
59	Telomere length and epigenetic clocks as markers of cellular aging: a comparative study. <i>GeroScience</i> , 2022, 44, 1861-1869.	4.6	18
60	Genetic testing in severe aplastic anemia is required for optimal hematopoietic cell transplant outcomes. <i>Blood</i> , 2022, 140, 909-921.	1.4	18
61	Benign tumors in myotonic dystrophy type I target disease-related cancer sites. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1510-1518.	3.7	16
62	Evidence-based care for breast cancer survivors: Communicating the Institute of Medicine Guidelines in medical practice. <i>Patient Education and Counseling</i> , 2009, 77, 413-420.	2.2	15
63	Donor telomere length and causes of death after unrelated hematopoietic cell transplantation in patients with marrow failure. <i>Blood</i> , 2018, 131, 2393-2398.	1.4	15
64	Benign and malignant tumors in the UK myotonic dystrophy patient registry. <i>Muscle and Nerve</i> , 2018, 57, 316-320.	2.2	15
65	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. <i>Genome Medicine</i> , 2018, 10, 99.	8.2	15
66	Brain tumors in patients with myotonic dystrophy: a population-based study. <i>European Journal of Neurology</i> , 2016, 23, 542-547.	3.3	14
67	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
68	Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. <i>JAMA Pediatrics</i> , 2019, 173, e190081.	6.2	14
69	Comparison of outcomes of HCT in blast phase of <i>t(9;22) BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	5.2	14
70	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
71	Oral cancer exams among cigarette smokers in Maryland. <i>Cancer Detection and Prevention</i> , 2006, 30, 499-506.	2.1	13
72	Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy. <i>European Journal of Neurology</i> , 2017, 24, 713-718.	3.3	13

#	ARTICLE	IF	CITATIONS
73	No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 383-391.	2.4	13
74	Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder. <i>ERJ Open Research</i> , 2019, 5, 00209-2019.	2.6	13
75	Diabetes, metformin and cancer risk in myotonic dystrophy type I. <i>International Journal of Cancer</i> , 2020, 147, 785-792.	5.1	13
76	Comparison of total body irradiation <i>versus</i> non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. <i>Haematologica</i> , 2021, 106, 1839-1845.	3.5	13
77	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 410-422.	1.2	13
78	Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia. <i>Journal of Viral Hepatitis</i> , 2011, 18, 161-169.	2.0	12
79	Bcl-2 level as a biomarker for 13q14 deletion in CLL. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 237-247.	1.5	12
80	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	5.2	12
81	Risk factors for Burkitt lymphoma: a nested case-control study in the <sc>UK</sc> Clinical Practice Research Datalink. <i>British Journal of Haematology</i> , 2018, 181, 505-514.	2.5	11
82	DNA-methylation-based telomere length estimator: comparisons with measurements from flow FISH and qPCR. <i>Aging</i> , 2021, 13, 14675-14686.	3.1	11
83	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 310-320.	1.2	11
84	Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 407-417.	2.5	10
85	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 480-487.	2.0	10
86	NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2014, 49, 561-566.	2.4	9
87	Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1054-1058.	2.0	9
88	Chromosomal Aberrations and Survival after Unrelated Donor Hematopoietic Stem Cell Transplant in Patients with Fanconi Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2003-2008.	2.0	9
89	Survival patterns and cancer determinants in families with myotonic dystrophy type 1. <i>European Journal of Neurology</i> , 2019, 26, 58-65.	3.3	9
90	Benefits of combining prevalent and incident cohorts: An application to myotonic dystrophy. <i>Statistical Methods in Medical Research</i> , 2019, 28, 3333-3345.	1.5	9

#	ARTICLE	IF	CITATIONS
91	Pre-transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia. <i>British Journal of Haematology</i> , 2020, 188, 309-316.	2.5	9
92	Menopausal hormone therapy and risk of biliary tract cancers. <i>Hepatology</i> , 2022, 75, 309-321.	7.3	9
93	A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantation. <i>Blood</i> , 0, , .	1.4	9
94	Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. <i>Lancet Haematology</i> , the, 2020, 7, e715-e723.	4.6	8
95	Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 313.e1-313.e8.	1.2	8
96	Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 607-614.	2.5	7
97	Cancer Risk Assessment for the Primary Care Physician. <i>Primary Care - Clinics in Office Practice</i> , 2009, 36, 471-488.	1.6	6
98	Editorial: US Cancer Statistics of Survival: Achievements, Challenges, and Future Directions. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	6
99	Risk factors for inflammatory and non-inflammatory breast cancer in North Africa. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 543-558.	2.5	6
100	Population Frequency of Fanconi Pathway Gene Variants and Their Association with Survival After Hematopoietic Cell Transplantation for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 817-822.	2.0	6
101	Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT. <i>Blood Advances</i> , 2021, 5, 66-70.	5.2	6
102	Nicotine dependence among adult male smokers in rural Egypt. <i>Journal of the Egyptian Society of Parasitology</i> , 2003, 33, 1019-30.	0.2	6
103	Reproductive Cancer Risk Factors in Women With Myotonic Dystrophy (DM): Survey Data From the US and UK DM Registries. <i>Frontiers in Neurology</i> , 2019, 10, 1071.	2.4	5
104	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	5.2	5
105	The role of 5 α -reductase inhibitors in gastroesophageal cancer risk: A nested case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 48-56.	1.9	4
106	Leukocyte telomere length in patients with myotonic dystrophy type I: a pilot study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 126-131.	3.7	4
107	Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia. <i>Scientific Reports</i> , 2021, 11, 15004.	3.3	4
108	Correlation of Telomere Length in Blood, Buccal Cells, and Fibroblasts From Patients with Inherited Bone Marrow Failure Syndromes.. <i>Blood</i> , 2009, 114, 1083-1083.	1.4	4

#	ARTICLE	IF	CITATIONS
109	Clonal Alterations and Survival after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant in Patients with Fanconi Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S119-S120.	2.0	3
110	Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 142.e1-142.e11.	1.2	3
111	Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 712.e1-712.e8.	1.2	3
112	Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 926.e1-926.e10.	1.2	2
113	De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Transplant Blood Samples. <i>Blood</i> , 2019, 134, 1430-1430.	1.4	2
114	Polychlorinated Biphenyls and Cancer: Are Telomeres to Blame?. <i>EBioMedicine</i> , 2015, 2, 1856-1857.	6.1	1
115	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 932-937.	2.4	1
116	Drug-Wide Association Study (DWAS): Challenges and Opportunities. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 597-599.	2.5	1
117	Donor Telomere Length and Outcomes after Allogeneic Unrelated Hematopoietic Cell Transplant in Patients with Acute Leukemia. <i>Blood</i> , 2016, 128, 520-520.	1.4	1
118	Abstract 5100: Development of a direct-measurement molecular assay to determine telomere length in human samples. <i>Cancer Research</i> , 2014, 74, 5100-5100.	0.9	1
119	Survival Modelling for Data From Combined Cohorts: Opening the Door to Meta Survival Analyses and Survival Analysis Using Electronic Health Records. <i>International Statistical Review</i> , 2023, 91, 72-87.	1.9	1
120	Enhancing a Cancer Prevention and Control Curriculum Through Interactive Group Discussions. <i>Journal of Cancer Education</i> , 2012, 27, 428-435.	1.3	0
121	Donor Telomere Length Predicts Recipient Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Bone Marrow Failure Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S33-S34.	2.0	0
122	Survival Trends after Allogeneic Hematopoietic Cell Transplant (HCT) in Children Less Than One-Year-Old (Infants). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S116.	2.0	0
123	Prognostic Impact of Pre-Transplant Chromosomal Aberrations Detected By SNP-Array in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplant for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S12-S13.	2.0	0
124	Multimodal Bcl-2 Sub-Populations in CLL. <i>Blood</i> , 2009, 114, 4391-4391.	1.4	0
125	Germline Mutations in Patients Receiving Unrelated Donor Hematopoietic Cell Transplant for Severe Aplastic Anemia. <i>Blood</i> , 2016, 128, 68-68.	1.4	0
126	Abstract 1237: Cancer risk in myotonic dystrophy type I: First evidence of a role for disease severity. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
127	Donor IFNL4 Genotype Is Associated with Transplant-Related Mortality after Unrelated Donor Myeloablative Hematopoietic Cell Transplantation in Patients with Acute Leukemia. <i>Blood</i> , 2018, 132, 968-968.	1.4	0
128	Genome-Wide Association Study Identifies an Immune-Related Etiology for Severe Aplastic Anemia. <i>Blood</i> , 2019, 134, 1224-1224.	1.4	0
129	Telomere length in hematopoietic cell transplant. <i>Blood</i> , 2020, 136, 2972-2973.	1.4	0
130	Readers respond to "balancing evidence-based medicine and cultural competence in the quest to end healthcare disparities". <i>MedGenMed: Medscape General Medicine</i> , 2006, 8, 73; author reply 24.	0.2	0
131	Whole Exome Sequencing in Severe Aplastic Anemia Identifies Unrecognized Inherited Subset with Inferior Survival after Hematopoietic Cell Transplant. <i>Blood</i> , 2021, 138, 605-605.	1.4	0
132	Germline-Somatic Interactions in Myelofibrosis Susceptibility. <i>Blood</i> , 2021, 138, 313-313.	1.4	0
133	Chromosomal Aberrations in Pre-HCT Blood Samples and Outcomes after Transplantation in Patients with Myelofibrosis. <i>Blood</i> , 2020, 136, 4-5.	1.4	0
134	Pre-Transplant Clonal Mosaicism Is Associated with Increased Relapse and Lower Survival in Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
135	Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching. <i>Blood</i> , 2020, 136, 24-26.	1.4	0